GeNeuro’s Pipeline Overview
GeNeuro's novel approach primarily focuses on the development of therapeutic monoclonal antibodies, which will target and neutralize the pathogenic proteins of the MSRV retrovirus. The therapeutic antibodies will prevent the initiation of the inflammatory and autoimmune cascades induced by these proteins in Multiple Sclerosis. A similar approach is applied for Schizophrenia.
These antibodies have now been tested in new experimental models developed by GeNeuro and have shown good efficacy properties, both in vitro and in vivo, with no evidence of adverse effect in in vivo models.
Unlike other drugs currently used to treat Multiple Sclerosis, which are aimed at slowing down the neurological damage and disability caused by the disease, GeNeuro's approach is directed upstream of the inflammatory demyelinating cascade, at the origin of the brain lesions.
GeNeuro is also developing diagnostic tests to dose the MSRV-Env protein in patients. These tests will be able to detect the presence of the antigen in the blood of the patients.